Sequent Scientific Share Price

Sequent Scien.

CMP as on 20-May-22 9:16

₹ 114.25
2.65 2.37%

Open

₹ 113.25

Turnover (lac)

₹ 14

Prev. Close

₹ 111.60

Day's Vol (shares)

₹ 12,585

Day's Range (₹)

₹ 113.25
₹ 114.85

CMP as on20-May-22 9:16

₹ 114.55
2.95 2.64%

Open

₹ 113.85

Turnover (lac)

₹ 620

Prev. Close

₹ 111.60

Day's Vol (shares)

₹ 579

Day's Range

₹ 113.70
₹ 114.80

Corporate Action

Go
Purpose AGM Date Announcement Date Book Closure Start Date Book Closure End Date
Board Meeting - 04-Feb-2022 - -
SEQUENT SCIENTIFIC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2022 inter alia to consider and approve Dear Sir/Madam Pursuant to Regulation 29(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 this is to inform you that the Meeting of the Board of Directors of SeQuent Scientific Limited (the Company) is scheduled to be held on Friday February 11 2022 inter-alia to consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and nine months ended December 31 2021 as required under Regulation 33 of the Listing Regulations. Further in continuation to our intimation dated December 31 2021 and pursuant to Companys Code of Conduct to Regulate Monitor and Report Trading by Designated Persons and their Immediate Relatives the trading window for dealing in the securities of the Company is closed from January 01 2022 till 48 hours after the declaration of Unaudited Financial Results of the Company for the quarter and nine months ended on December 31 2021. Kindly take the above on records. Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2021. (As per BSE Announcement Dated on 11/02/2022)
Board Meeting - 14-Jan-2022 - -
Pursuant to Regulation 30 read with Part A, Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (LODR Regulations), we wish to inform you that the Board of Directors of the Company has taken on record/approved the following changes in the composition of the Board of Directors at its meeting held on January 14, 2022: Name of Director Resignation/Appointment: Mr. Manish Gupta (DIN: 06805265) Resigned as a Managing Director and Chief Executive Officer (MD & CEO) of the Company with effect from April 10, 2022. Mr. Rajaram Narayanan (DIN: 02977405) Appointed as MD & CEO of the Company for a period of 5 years, with effect from April 11, 2022. The appointment is subject to the approval of shareholders of the Company, which shall be sought separately.
Board Meeting - 25-Oct-2021 - -
Quarterly Results Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2021. (As per BSE Announcement Dated on 01/11/2021)
Board Meeting - 04-Aug-2021 - -
SEQUENT SCIENTIFIC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2021 ,inter alia, to consider and approve Dear Sir/Madam, Pursuant to Regulation 29(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Meeting of the Board of Directors of SeQuent Scientific Limited (the Company) is scheduled to be held on Tuesday, August 10, 2021 inter-alia, to consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended June 30, 2021 as required under Regulation 33 of the Listing Regulations. Further, in continuation of our intimation dated June 30, 2021 and pursuant to Companys Code of Conduct to Regulate, Monitor and Report Trading by Designated Persons and their Immediate Relatives, the trading window for dealing in the securities of the Company is closed from July 01, 2021 till 48 hours after the declaration of Unaudited Financial Results of the Company for the quarter ended June 30, 2021. Kindly take the above on records. Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2021. In this regard, kindly find enclosed the following: 1. Unaudited Consolidated Financial Results along with Independent Auditors Review Report issued by the Statutory Auditors of the Company for the quarter ended June 30, 2021. 2. Unaudited Standalone Financial Results along with Independent Auditors Review Report issued by the Statutory Auditors of the Company for the quarter ended June 30, 2021. 3. A copy of Press Release and Investors Presentation on Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2021. (As per BSE Announcement Dated on 10/8/2021)
Board Meeting - 24-Jun-2021 - -
Sequent Scientific Ltd has informed BSE that the Meeting of the Board of Directors of the Company is scheduled to be held on June 30, 2021, inter alia, to consider and approve:1. The Standalone and Consolidated Audited Financial Results of the Company for the quarter and year ended March 31, 2021.2. recommendation of dividend, if any, for the financial year ended March 31, 2021. The Board of Directors at their meeting held today have recommended a final dividend of Rs. 0.50 (25%) per equity share for the financial year ended March 31, 2021. Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered and approved the Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2021. In this regard, kindly find enclosed the following (As per BSE Announcement dated on 30/06/2021)
Open ZERO Brokerage Demat Account Open Demat Account

  • 0

    Per Order for ETF & Mutual Funds Brokerage

  • 20

    Per Order for Delivery, Intraday, F&O, Currency & Commodity